Clinical Trial Update: In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating in-vivo regulatory T cell enhancement using cyclophosphamide and sirolimus for graft-versus-host disease was terminated, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Sirolimus (Sirolimus)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Graft Versus Host Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-03-02